Skip to content

effect of folic acid in treatment of periodontitis

The effect of the systemic folic acid administration as an adjunct to scaling and root planing on clinical parameters and serum level of C-reactive protein in patients with periodontitis : A randomized placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251002067477N1
Enrollment
56
Registered
2026-04-05
Start date
2026-01-21
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis. Chronic periodontitis

Interventions

Intervention 1: Intervention group: Scaling and root planing with administration of folic acid tablets (1 mg - Raha Pharmaceutical Company – Iran) once daily for four weeks
tablets are taken during meals and consumption with milk or dairy products is avoided. Intervention 2: Control group: Scaling and root planing with administration of placebo tablets (containing an ina

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
31 Years to 61 Years

Inclusion criteria

Inclusion criteria: Patients aged 31 to 61 years at least 8 pockets with a depth of 5 mm or more a clinical attachment level (CAL) of =4 mm stage II-III periodontitis (corresponding to "moderate to severe" in the previous classification).

Exclusion criteria

Exclusion criteria: Have systemic conditions including anemia, diabetes, immunodeficiency, malignancy, bone metabolic diseases/disorders, renal or thyroid dysfunction, radiotherapy, treatment with immunosuppressive agents, or gastrointestinal diseases. Patients who consume alcohol, smokers, obese individuals, or those who are pregnant or breastfeeding. have received periodontal treatment within the past year. have received anti-inflammatory or antimicrobial treatment, or iron/vitamin supplements within the past three months. lack of cooperation.

Design outcomes

Primary

MeasureTime frame
Clinical attachment level. Timepoint: before treatment and at 1-month and 3-month periods after treatment . Method of measurement: William's periodontal probe.

Secondary

MeasureTime frame
Plaque index. Timepoint: before treatment and at 1-month and 3-month periods after treatment. Method of measurement: The Plaque Index (PI) has 4 scores, each defined as follows: Score 0: No plaque Score 1: Plaque becomes visible after moving the probe along the gum line Score 2: Visible plaque Score 3: Abundant plaque.;Gingival index. Timepoint: before treatment and at 1-month and 3-month periods after treatment. Method of measurement: The Gingival Index (GI) has 4 scores, each defined as follows: Score 0: Absence of visible signs of gingival inflammation Score 1: Slight change in the color and surface texture of the gingiva Score 2: Visible inflammation and tendency for bleeding from the gingival margin immediately after probing Score 3: Severe inflammation and tendency for spontaneous bleeding.;Pocket depth. Timepoint: before treatment and at 1-month and 3-month periods after treatment . Method of measurement: William's periodontal probe ( millimeter).;Gingival recession. Timepoint: before treatment and at 1-month and 3-month periods after treatment. Method of measurement: William's periodontal probe ( millimeter).;C-Reactive Protein (CRP) serum level. Timepoint: before treatment and at 1-month and 3-month periods after treatment . Method of measurement: The level of C-reactive protein in the blood (mg/L), measured using a Biorex kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Azizi

Yazd University of Medical Sciences

saharazizi.dnt@gmail.com+98 35 3620 4761

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026